The Peter Attia Drive

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

22 min

This AMA episode of The Peter Attia Drive tackles the complex and often confusing world of peptides, distinguishing between FDA-approved therapeutics and the unregulated "biohacking" compounds. Peter Attia introduces a comprehensive framework for evaluating any peptide based on its mechanism, efficacy, safety, and available alternatives, aiming to help listeners discern science from marketing hype. The discussion also delves into the gray market for peptides and categorizes them into four evidence-based buckets.

Summarized by Podsumo

🎧 Listen 🎙️ Ask about this episode

✨ Key Takeaways

1

Peptide Evaluation Framework

Peter Attia provides a structured approach to assess any peptide, emphasizing the need for a viable mechanism of action, evidence of intended effects and safety in humans, and consideration of legitimate alternatives.
2

Distinction between Approved vs. "Biohacking" Peptides

The episode differentiates between FDA-approved peptide therapeutics (like insulin or GLP-1 agonists) and the largely unregulated compounds popular in the wellness and longevity space, often sold as "research use only."
3

Four Evidence-Based Buckets

Peptides are categorized into four groups based on their scientific backing: from no compelling case, to abandoned clinical trials, to those in trials/approved for other uses, and finally, "stolen" FDA-approved drugs sold illegally.
4

Gray Market Concerns

The discussion highlights critical issues surrounding manufacturing, sales, and the "research use only" designation in the gray market, questioning the reliability of third-party testing and the lack of regulatory oversight.
5

Specific Examples

The episode promises to apply the evaluation framework to popular peptides such as SS-31, Melanotan II, CJC-1295, and BPC-157 to illustrate the practical application of the assessment process.

💬 Notable Quotes

"Peptides sit at the intersection of biological plausibility, clinical promise, and rampant commercialization."
"The reality is that the peptide ecosystem is sprawling, poorly regulated, and filled with claims that range from legitimate to completely ungrounded."
"If there's no mechanism of action, you should be very skeptical of a drug or supplement."